3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Thyroid Cancer, Papillary
3
Colonic Neoplasms
3
Carcinoma, Medullary
3
Thyroid Neoplasms
2
Thyroid Diseases
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms by Site
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Sarcoma
1
Pancreatic Neoplasms
1
Myofibromatosis
1
Gastrointestinal Neoplasms
1
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
selpercatinib
×
Breast
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled